Dosing & Uses
Dosage Forms & Strengths
Initial: 250 mcg IM; THEN repeat PRN q1.5-3.5hr OR
An initial, optional test dose of 100 mcg IM; THEN increase dose to 500 mcg if response is inadequate with 250 mcg doses
No more than 1200 mcg total dose or 2 days of continuous administration
Refractory Postpartum Uterine Bleeding
Initial 250 mcg IM, repeat PRN q15-90min
No more than 2000 mcg or 8 doses
Serious - Use Alternative
Significant - Monitor Closely
Frequency Not Defined
Effects due to increased smooth muscle contractility most common
Nausea (1/3 patients), Vomiting (~2/3 patients)
Diarrhea (~2/3 patients)
Posterior cervical perforation
Urinary tract infection
Uterine bleeding (excessive)
Local: injection site pain
Upper respiratory tract infection
Retained placental fragment
Black Box Warning
Potent oxytocic agent; use strict aderence to recommended dosing
Only medically-trained personnel should administer the product in a hospital setting that can provide immediate care and acute surgical facilities
Acute pelvic inflammatory disease
Active cardiac, pulmonary, renal or hepatic disease
History of glaucoma or raised IOP
Asthma, hypertension/hypotension, cardiovascular disease
Transient fever observed with treatment possibly as a result of carboprost's effect on hypothalamic thermoregulation
Caution in patients with anemia, jaundice, renal impairment, hepatic impairment diabetes or epilepsy
To decrease GI side effects pretreatment or concomitant use with antiemetic and antidiarrheal agents recommended
Not for IV
Rare cases of cardiovascular collapse reported with prostaglandins
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Excretion in milk unknown
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Inhibits or stimulates smooth muscle contraction, which results in expulsion of the products of conception and is used to induce abortion between 13-20 weeks of pregnancy; inhibits release of norepinephrine or modulates its effects at neuroeffector sites
Peak plasma time: 20-30 min
Concentration: 1-1.6 ng/mL
Half-life: 3 hr
Protein bound: None
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.